Patent ID: 7674775
Filing Date: 2010-03-09
Classification: A61P,C07F

Abstract:
1. A method of treatment of cancer in a vertebrate in need of said treatment, wherein said method comprises administering to the vertebrate a therapeutically effective amount of a compound according to the Formula (I) or salt thereof, each alone or together with a pharmaceutically acceptable carrier, adjuvant and/or diluent: wherein A is selected from the group consisting of glutathione, glucosamine, cysteinylglycine, cysteic acid, aspartic acid, glutamic acid, lysine, and arginine, and wherein the sulfur atom of each sulfur containing compound may be optionally oxidised to form a sulfoxide or sulfone; X is selected from the group consisting of: NR—, S(O)—, —S(O)O—, —S(O) B is selected from C X′ is selected from NR—, —O—, —S—, —Se—, —S—S—, S(O)—, —OS(O)—, OS(O)O—, —OS(O) or is absent; wherein E is O, S, Se, NR or NR B′ is C each R is independently selected from hydrogen, C R′ is the same as R or two R′ may be taken together with the nitrogen atoms to which they are attached to form a 5 or 6-membered saturated or unsaturated heterocyclic ring; each R each R each R wherein for each instance that B and/or B′ is arylene, the substituents directly attached to the respective arylene rings (including arsenoxide) may be in a para, meta or ortho relationship, and wherein each alkylene, alkenylene, alkynylene, cycloalkylene, cycloalkenylene, heterocycloalkylene, heterocycloalkenylene, arylene, heteroarylene and acyl may be independently substituted with hydrogen, C wherein R, R 1 and R 5 are as defined above; and R each R each R R R″ is the same as R or two R″ taken together with the N atom to which they are attached may form a saturated, unsaturated or aromatic heterocyclic ring system; Q is selected from halogen and —OS(O) M is an integer selected from 1 to 5, Y comprises at least one arsenoxide group; p is an integer from 1 to 10; and wherein the sum total of carbon atoms in A and (XBX′)